繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

IPO Plus - IPO

To-be Listed (Grey Market Trading Session: 14:15-16:30)
Name▼
/
Code▲
 Industry Listing Price Lot Size Entry Fee Phillip Grey Market Futu (HK) Grey Market
Minieye Tec
02431.HK
Grey Market Today
 Application Software Pending 200 4,081
-
-
 Detail Quote
Last update: 2024-12-23 12:30:04
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
Xunfei Healthcare
02506.HK		 Application Software 82.8 50 N/A 2024/12/23 2024/12/27 2024/12/30
InnoScience
02577.HK		 Semiconductors & Semiconductor Equipment 30.86-33.66 100 3,400 2024/12/23 2024/12/27 2024/12/30
HealthyWay
02587.HK		 Health Care Services 7.8-8.8 500 4,444 2024/12/23 2024/12/27 2024/12/30
HEARTCARE-B (06609.HK)
Summary
We are an innovative neuro-interventional medical device company with an established leadership position in the neuro-intervention market in China by virtue of our broad portfolio of both commercialized products and product candidates. Our product portfolio includes both neuro-interventional and cardiac medical devices. Leveraging our capabilities in R&D, manufacturing and commercialization, we strive to reduce the mortality rate and improve prognosis of stroke in China and worldwide through the commercialization of our product candidates.

Our two Core Products are CaptorTM thrombectomy device (“Captor”), which is for acute ischemic stroke and has been commercialized in China, and left atrial appendage (LAA) occluder, which is for atrial fibrillation and is in NMPA registration review. Founded in June 2016, we have a broad portfolio of four commercialized products and 19 approved products and product candidates in China covering all major stroke subtypes and surgical pathways in the neuro-interventional field, while our ischemic stroke prevention product candidates also allow us to capture demands from the cardiac market. We have developed all of our products and product candidates in-house from design stage to the subsequent product registration and commercialization. Our portfolio extends from the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, to the treatment of hemorrhagic stroke. As of the Latest Practicable Date, we had commercialized four ischemic stroke treatment devices forming a complete product suite for stent retrieving thrombectomy procedures. We commenced sales for the thrombectomy device, the distal access catheter and microcatheter in the product suite in 2020 and for our balloon guiding catheter in April 2021. Additionally, we expect to commercialize nine product candidates in 2021 and commercialize another 10 product candidates between 2022 and 2025, including the global-first sirolimus intracranial drug- eluting balloon catheter for intracranial stenosis treatment, thereby further expanding and diversifying our product offerings for the unmet and differentiated needs of stroke patients.

Stroke is a leading cause of death and disability globally. In China, stroke was the top cause of death in 2019 as the incidence rate of stroke recorded continued increase in recent years largely driven by the aging of the Chinese population. Neuro-interventional technology innovations in recent years are revolutionizing the therapeutic and preventive practices in the field of stroke, causing a fundamental shift from the traditional anticoagulant drug treatment and intravenous thrombolysis to the new neuro-interventional procedures with proven safety and significantly enhanced efficacy according to papers published by third parties in internationally renowned scientific journals. According to CIC, the patient expenditure on medication therapy, open surgery and neuro-interventional procedures for ischemic stroke was RMB493.4 million, RMB1,273.3 million and RMB3,056.0 million, respectively; the patient expenditure by the same treatment options for hemorrhagic stroke was RMB1,118.7 million, RMB2,689.2 million and RMB4,195.1 million, respectively; and the patient expenditure by the same treatment options for intracranial stenosis was RMB63.9 million, RMB170.5 million and RMB2,060.0 million, respectively, in China in 2019. Our innovative and comprehensive product portfolio, with one global-first (sirolimus intracranial drug-eluting balloon catheter) and a number of domestic-first (Captor and Fullblock balloon guiding catheter) neuro- interventional devices, places us at the forefront of such fundamental shift.

China has a large patient pool of stroke. The number of stroke patients in China reached 14.8 million in 2019, including 11.9 million ischemic stroke patients and 2.9 million hemorrhagic stroke patients, and the annual incidence (occurrence of new cases of disease) of ischemic stroke reached 2.3 million in 2019, according to CIC. On the other hand, the penetration rate (measured by the number of procedures as a percentage of the number of patients eligible for such procedures) of neuro-interventional procedures in China was relatively low as compared to that of the developed countries. In the U.S., due to the American Heart Association (AHA) guideline’s recognition in 2015 of thrombectomy as the first-line treatment for ischemic stroke and the technology advancements, the penetration rate of thrombectomy procedures increased rapidly from 1.4% in 2015 to 11.8% in 2019. By comparison, the penetration rate of thrombectomy procedures in China stood at a mere 1.7% in 2019 but is expected to increase to 42.9% in 2030, benefiting from a combination of technology innovation, favorable government policies and rising per capita income and healthcare expenditure. As a front-runner in the China neuro-interventional device market, we aim to capture such growth in thrombectomy procedures between now and 2030 and solidify our established leadership position in the neuro-intervention market in China by virtue of our broad portfolio of both commercialized products and product candidates.

Source: HeartCare-B (06609) Prospectus (IPO Date : 2021/08/10)
Listing Market MAIN
Industry Biotechnology
Background H Shares
Major Business Area N/A
Corporate Information
Substantial Shareholders WANG Guohui (Total share: 29.20%); (H share: 25.83%)
LYFE Capital Management Limited (Total share: 13.64%); (H share: 16.78%)
Ding Kui & Associates (Total share: 8.15%); (H share: 7.55%)
ZHANG Kun (Total share: 8.07%); (H share: 4.96%)
Temasek Holdings (Private) Limited (Total share: 4.55%); (H share: 5.60%)
Directors WANG Guohui (Chairman and Chief Executive Officer and Executive Director)
ZHANG Kun (Deputy General Manager and Executive Director)
Wei Jiawei (Executive Director)
Ding Kui (Non-Executive Director)
Chen Shaoxiong (Non-Executive Director)
CHEN Gang (Non-Executive Director)
FENG Xiangqian (Independent Non-Executive Director)
GONG Ping (Independent Non-Executive Director)
GUO Shaomu (Independent Non-Executive Director)
Company Secretary Zhang Han
KWOK Siu Ying, Sarah
Principal Bankers China Merchants Bank
Solicitors All Bright Law Offices
O Melveny & Myers LLP
Auditors Ernst & Young
Registered Office Room 1901, 19th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Share Registrars Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No (852) 2862-8628
Internet Address http://www.heartcare.com.cn
Email Address info@heartcare.com.cn
Tel No (86 21) 5897-5056
Fax No
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.